Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

Time of catheter removal in candidemia and mortality.

Nucci M, Braga PR, Nouér SA, Anaissie E.

Braz J Infect Dis. 2018 Nov - Dec;22(6):455-461. doi: 10.1016/j.bjid.2018.10.278. Epub 2018 Nov 20.

2.

Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Mizuno K, Dong M, Fukuda T, Chandra S, Mehta PA, McConnell S, Anaissie EJ, Vinks AA.

Clin Pharmacokinet. 2018 May;57(5):625-636. doi: 10.1007/s40262-017-0581-x.

PMID:
28918602
3.

Fusariosis.

Nucci F, Nouér SA, Capone D, Anaissie E, Nucci M.

Semin Respir Crit Care Med. 2015 Oct;36(5):706-14. doi: 10.1055/s-0035-1562897. Epub 2015 Sep 23. Review.

PMID:
26398537
4.

Distinguishing the Causes of Pulmonary Infiltrates in Patients With Acute Leukemia.

Nucci M, Nouér SA, Anaissie E.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S98-103. doi: 10.1016/j.clml.2015.03.007.

PMID:
26297289
5.

Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms.

Nouér SA, Nucci M, Anaissie E.

Expert Rev Hematol. 2015 Oct;8(5):647-58. doi: 10.1586/17474086.2015.1060576. Epub 2015 Jun 26. Review.

PMID:
26115679
6.

How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach.

Nucci M, Anaissie E.

Blood. 2014 Dec 18;124(26):3858-69. doi: 10.1182/blood-2014-04-516211. Epub 2014 Oct 22.

7.

GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.

Coleman EA, Lee JY, Erickson SW, Goodwin JA, Sanathkumar N, Raj VR, Zhou D, McKelvey KD, Apewokin S, Stephens O, Enderlin CA, Vangsted AJ, Reed PJ, Anaissie EJ.

Support Care Cancer. 2015 Mar;23(3):841-9. doi: 10.1007/s00520-014-2406-x. Epub 2014 Sep 14.

8.

MicroRNA theragnostics for the clinical management of multiple myeloma.

Ahmad N, Haider S, Jagannathan S, Anaissie E, Driscoll JJ.

Leukemia. 2014 Apr;28(4):732-8. doi: 10.1038/leu.2013.262. Epub 2013 Sep 12. Review.

PMID:
24714346
9.

Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET).

Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, Alexander BD, Anaissie EJ, Benedict K, Ito JI, Knapp KM, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Schuster MG, Chiller TM, Pappas PG.

Transpl Infect Dis. 2014 Apr;16(2):213-24. doi: 10.1111/tid.12186. Epub 2014 Mar 4.

10.

Future directions in the clinical management of amyloid light-chain amyloidosis.

Haider S, Ahmad N, Anaissie E, Driscoll JJ.

Leuk Lymphoma. 2014 Oct;55(10):2241-51. doi: 10.3109/10428194.2013.876630. Epub 2014 Feb 24. Review.

PMID:
24359238
11.

Atypical B12 deficiency with nonresolving paraesthesia.

Haider S, Ahmad N, Anaissie EJ, Abdel Karim N.

Case Rep Oncol Med. 2013;2013:823842. doi: 10.1155/2013/823842. Epub 2013 Nov 18.

12.

Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome.

Nucci M, Nouér SA, Cappone D, Anaissie E.

Haematologica. 2013 Nov;98(11):1657-60. doi: 10.3324/haematol.2013.094359. No abstract available.

13.

Improvement in the outcome of invasive fusariosis in the last decade.

Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvão Castro C Jr, Herbrecht R, Hoenigl M, Härter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E.

Clin Microbiol Infect. 2014 Jun;20(6):580-5. doi: 10.1111/1469-0691.12409. Epub 2013 Nov 18.

14.

Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing.

Laínez JM, Orcun S, Pekny JF, Reklaitis GV, Suvannasankha A, Fausel C, Anaissie EJ, Blau GE.

Pharmacotherapy. 2014;34(4):330-5. doi: 10.1002/phar.1346. Epub 2013 Aug 27.

PMID:
24038448
15.

Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients.

Krishna SG, Zhao W, Apewokin SK, Krishna K, Chepyala P, Anaissie EJ.

Transpl Infect Dis. 2013 Oct;15(5):493-501. doi: 10.1111/tid.12112. Epub 2013 Aug 27.

PMID:
24034141
16.

Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant.

Muzaffar J, Katragadda L, Haider S, Abdallah AO, Anaissie E, Usmani SZ.

Acta Haematol. 2013;130(3):146-9. doi: 10.1159/000347036. Epub 2013 May 9.

PMID:
23689541
17.

Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.

Amsden JR, Gubbins PO, McConnell S, Anaissie E.

Antimicrob Agents Chemother. 2013 Jul;57(7):3420-3. doi: 10.1128/AAC.00046-13. Epub 2013 Apr 29.

18.

Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease.

Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E.

Transpl Infect Dis. 2013 Aug;15(4):354-60. doi: 10.1111/tid.12067. Epub 2013 Apr 11.

PMID:
23578205
19.

Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study.

Blau GE, Orcun S, Laínez JM, Reklaitis GV, Suvannasankha A, Fausel C, Anaissie EJ.

Pharmacotherapy. 2013 Jul;33(7):727-35. doi: 10.1002/phar.1267. Epub 2013 Apr 3.

PMID:
23553679
20.

High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience.

Muzaffar J, Usmani S, Abdallah AO, Anaissie E, Cottler-Fox M, Restrepo A.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):171-4. doi: 10.1016/j.clml.2012.12.004. Epub 2013 Jan 10. No abstract available.

PMID:
23313066
21.

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B.

Blood. 2013 Mar 7;121(10):1819-23. doi: 10.1182/blood-2012-08-451690. Epub 2013 Jan 10.

22.

Effects of exercise on fatigue, sleep, and performance: a randomized trial.

Coleman EA, Goodwin JA, Kennedy R, Coon SK, Richards K, Enderlin C, Stewart CB, McNatt P, Lockhart K, Anaissie EJ.

Oncol Nurs Forum. 2012 Sep;39(5):468-77. doi: 10.1188/12.ONF.468-477.

23.

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL.

J Infect. 2012 Nov;65(5):453-64. doi: 10.1016/j.jinf.2012.08.003. Epub 2012 Aug 13.

PMID:
22898389
24.

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD Jr, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B.

Clin Cancer Res. 2012 Oct 1;18(19):5499-506. doi: 10.1158/1078-0432.CCR-12-0019. Epub 2012 Aug 1. Erratum in: Clin Cancer Res. 2013 Feb 1;19(3):752.

25.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B.

Haematologica. 2013 Jan;98(1):71-8. doi: 10.3324/haematol.2012.066555. Epub 2012 Jun 24.

26.

Far-reaching conclusions based on weak and missing data.

Anaissie E, Nucci M.

Clin Infect Dis. 2012 Sep;55(6):890-3; author reply 894-5. doi: 10.1093/cid/cis521. Epub 2012 Jun 18. No abstract available.

PMID:
22711067
27.

Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis.

Nouér SA, Nucci M, Kumar NS, Grazziutti M, Restrepo A, Anaissie E.

Clin Infect Dis. 2012 Jun;54(12):e173-83. doi: 10.1093/cid/cis298. Epub 2012 Mar 15.

28.

Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature.

Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S.

Int J Hematol. 2012 Jan;95(1):102-6. doi: 10.1007/s12185-011-0968-7. Epub 2011 Dec 15. Review.

PMID:
22170228
29.

Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.

Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, Kontoyiannis DP.

Emerg Infect Dis. 2011 Oct;17(10):1855-64. doi: 10.3201/eid1710.110087.

30.

Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition.

Nouér SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E.

Clin Infect Dis. 2011 Oct;53(7):671-6. doi: 10.1093/cid/cir441. Epub 2011 Aug 16.

31.

The surgical management of abdominal pain in the multiple myeloma patient.

Garrett J, Klimberg VS, Anaissie E, Barlogie B, Turnage R, Badgwell BD.

Am J Surg. 2012 Feb;203(2):127-31. doi: 10.1016/j.amjsurg.2011.02.012. Epub 2011 Jul 23.

PMID:
21788006
32.

Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.

Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, Coon SK, Bailey C, Barlogie B.

Cancer. 2012 Jan 15;118(2):549-57. doi: 10.1002/cncr.26302. Epub 2011 Jun 30.

33.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.

34.

Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma.

Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, Stewart CB, McNatt P, Lockhart K, Anaissie EJ, Barlogie B.

Cancer Nurs. 2011 May-Jun;34(3):219-27. doi: 10.1097/NCC.0b013e3181f9904d.

35.

Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies.

Nucci M, Nouér SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E.

Clin Infect Dis. 2010 Dec 1;51(11):1273-80. doi: 10.1086/657065. Epub 2010 Oct 29.

PMID:
21034199
36.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13. Erratum in: Cancer. 2011 Jul 1;117(13):3060.

37.

Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications.

Krishna SG, Zhao W, Grazziutti ML, Sanathkumar N, Barlogie B, Anaissie EJ.

Cancer. 2011 Feb 1;117(3):648-55. doi: 10.1002/cncr.25633. Epub 2010 Sep 22.

38.

Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.

Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O.

Clin Infect Dis. 2010 Aug 1;51(3):295-303. doi: 10.1086/653935.

PMID:
20578829
39.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Barlogie B.

Blood. 2010 Aug 26;116(8):1220-7. doi: 10.1182/blood-2010-01-264333. Epub 2010 May 25.

40.

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr, Szymonifka J, Hoering A, Petty N, Crowley J.

J Clin Oncol. 2010 Jun 20;28(18):3023-7. doi: 10.1200/JCO.2009.26.4465. Epub 2010 May 17.

41.

Factors associated with mortality in transplant patients with invasive aspergillosis.

Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG.

Clin Infect Dis. 2010 Jun 15;50(12):1559-67. doi: 10.1086/652768.

42.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD Jr.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7904-9. doi: 10.1073/pnas.0908441107. Epub 2010 Apr 12.

43.

Recurrent spontaneous gastrointestinal graft-versus-host disease in autologous hematopoietic stem cell transplantation.

Krishna SG, Barlogie B, Lamps LW, Krishna K, Aduli F, Anaissie E.

Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E17-21. doi: 10.3816/CLML.2010.n.012.

PMID:
20223723
44.

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG.

Clin Infect Dis. 2010 Apr 15;50(8):1091-100. doi: 10.1086/651263.

PMID:
20218877
45.

Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM.

Clin Infect Dis. 2010 Apr 15;50(8):1101-11. doi: 10.1086/651262.

PMID:
20218876
46.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.

47.

Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients.

Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, Pfaller M, Steinbach WJ, Webster KM, Marr KA.

Transpl Infect Dis. 2010 Jun;12(3):220-9. doi: 10.1111/j.1399-3062.2010.00492.x. Epub 2010 Jan 25.

PMID:
20113459
48.

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.

Nucci M, Anaissie E.

Clin Infect Dis. 2009 Oct 15;49(8):1211-25. doi: 10.1086/605664. Review.

PMID:
19769539
49.

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2009 Nov;147(3):347-51. doi: 10.1111/j.1365-2141.2009.07864.x. Epub 2009 Aug 21.

50.

Infections in patients with multiple myeloma.

Nucci M, Anaissie E.

Semin Hematol. 2009 Jul;46(3):277-88. doi: 10.1053/j.seminhematol.2009.03.006. Review.

PMID:
19549580

Supplemental Content

Loading ...
Support Center